The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer.
 
Aaron James Scott
No Relationships to Disclose
 
Bert H. O'Neil
Consulting or Advisory Role - Acceleron Pharma; Amgen; Genentech/Roche; Sanofi
Speakers' Bureau - Amgen
Research Funding - Novartis (Inst)
 
Christina Gomes
Employment - The Oncology Consortia of Criterium
 
Joaquina Celebre Baranda
Research Funding - Novartis
 
Steven J. Cohen
No Relationships to Disclose
 
Mohamedtaki Abdulaziz Tejani
No Relationships to Disclose
 
Robert T. Maguire
Employment - Wyeth
 
Francois Wilhelm
Employment - Onconova Therapeutics
 
Manoj Maniar
Employment - Onconova Therapeutics
 
Deirdre Jill Cohen
No Relationships to Disclose
 
Wen Wee Ma
Research Funding - Onconova Therapeutics (Inst)
 
Dara Aisner
Honoraria - Illumina
Consulting or Advisory Role - Boehringer Ingelheim; Oxford Oncology
 
Jonathan K. Cho
No Relationships to Disclose
 
Olugbenga Olanrele Olowokure
No Relationships to Disclose
 
Andrew L. Coveler
No Relationships to Disclose
 
Alex R. Menter
No Relationships to Disclose
 
Peter Rubin
No Relationships to Disclose
 
Mike Cusnir
No Relationships to Disclose
 
Wells A. Messersmith
Research Funding - Onconova Therapeutics